📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

A randomized, open-label trial of combined nitazoxanide and atazanavir/ritonavir for mild to moderate COVID-19 (2022)

First Author: Fowotade A

Attributed to: New Branched Polymers Excipients and Emulsions for Enhanced Drug Delivery funded by EPSRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.3389/fmed.2022.956123

PubMed Identifier: 36160134

Publication URI: http://europepmc.org/abstract/MED/36160134

Type: Journal Article/Review

Parent Publication: Frontiers in Medicine

ISSN: 2296-858X